This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Invest in Abiomed (ABMD) Right Now
by Zacks Equity Research
Abiomed (ABMD) continues to gain from its flagship Impella; a strong fiscal 2019 outlook encourages.
Here's Why You Should Invest in Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Hill-Rom (HRC) focuses on product innovation. Through fiscal 2018, new products generated more than $300 million in revenues.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Strength in the surgical platform and an upbeat view for 2018 make Intuitive Surgical (ISRG) a promising pick.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.
Zacks.com featured highlights include: K12, Great Lakes Dredge, Luxfer, Integer Holdings and STAAR
by Zacks Equity Research
Zacks.com featured highlights include: K12, Great Lakes Dredge, Luxfer, Integer Holdings and STAAR
5 Stocks With Recent Price Strength to Maximize Your Gains
by Zacks Equity Research
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Integer Holdings (ITGR) Beats on Q3 Earnings and Revenues
by Zacks Equity Research
Integer Holdings (ITGR) gains from solid Medical sales contribution in Q3; 2018 guidance solid.
Integer (ITGR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 15.22% and 4.48%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Integer Holdings (ITGR) in Q3 Earnings?
by Zacks Equity Research
The Cardio & Vascular product line to boost Integer Holdings' (ITGR) top line in Q3. The upside will be driven by strong revenues in the peripheral vascular, neurovascular and electrophysiology markets.
Integer (ITGR) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold Integer Holdings in Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) new strategy to drive sales and profit growth to provide the company with a competitive edge in the MedTech space.
Medtronic (MDT) Initiates ONYX ONE- Clear Study on DAPT
by Zacks Equity Research
Following a DAPT interruption at one month on patients with a next generation DES, the Onyx ONE Clear Study by Medtronic (MDT) investigates risk of cardiac death, heart attack and stent thrombosis.
Integra Lifesciences Picked for Healogics iSupply Program
by Zacks Equity Research
Integra Lifesciences' (IART) selection as a key provider for cellular-based tissue products within Healogics' new iSupply program to boost the top line.
IDEXX Gains Ground on Solid CAG Business Amid Forex Woes
by Zacks Equity Research
IDEXX (IDXX) continues to see strong organic growth, driven by solid sales at the CAG business. However, unfavorable currency movement remains a concern.
Abbott's DRG Therapy Now Covered by Aetna, To Boost Uptake
by Zacks Equity Research
Abbott (ABT) to see a rise in customer adoption of its DRG therapy following the receipt of new national coverage from Aetna.
Here's Why You Should Hold On to Quest Diagnostics (DGX) Now
by Zacks Equity Research
Tough competitive landscape and reimbursement issues are major deterrents to Quest Diagnostics' (DGX) top line in the near term. The company's focus on promising areas to drive growth is a positive.
Boston Scientific to Boost MedSurg Unit Via Augmenix Buyout
by Zacks Equity Research
Boston Scientific (BSX) continues to adopt organic as well as inorganic means to boost top line.
Penumbra Launches Reperfusion Catheters, Boosts Neuro Unit
by Zacks Equity Research
Penumbra (PEN) adopts initiatives to boost the highest revenue generating Neuro business.
Neogen's Livestock Genetic Buyout Expands Animal Safety Suite
by Zacks Equity Research
The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.
Genomic Health Prostate Cancer Business Solid, Cost Woes Stay
by Zacks Equity Research
Within the prostate cancer space, Genomic Health (GHDX) is seeing increasing private coverage for the Oncotype DX GPS test. Costs and operating expenses continue to rise.
Here's Why You Should Invest in athenahealth (ATHN) Now
by Zacks Equity Research
Focus on cloud-based services and a lifted guidance for 2018 make athenahealth (ATHN) an attractive pick.
HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.
Here's Why You Should Hold On to Baxter (BAX) Stock Now
by Zacks Equity Research
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.
Why Integer (ITGR) is a Top Pick for Momentum Investors
by Zacks Equity Research
Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Amedisys Ties Up With Medalogix to Boost Home Health Unit
by Zacks Equity Research
Amedisys (AMED) pursues deals to boost Home Health business.